Noncolligative properties of intravenous fluids.
OBJECTIVE
Currently available crystalloids were designed over a century ago for dehydration and not for the treatment of hemorrhagic shock. Information regarding fluids used for resuscitation has grown and thus resuscitation has changed radically in the last two decades. Artificial fluids such as crystalloids and other solutions typically used for resuscitation are now recognized to be inflammatory when infused at high volumes to replace blood.


RESULTS
Recent studies have shown that the crystalloids and artificial colloids cause inflammation. Prehospital fluid use has not shown to be of benefit and permissive hypotension may be useful. Careful titration of fluids with minimizing crystalloids and early use of blood products have improved outcome after traumatic hemorrhagic shock.


CONCLUSIONS
Seemingly innocuous fluids have a dose effect and can be detrimental. Crystalloids can create inflammation when used at high volumes and may be the reason for the sequelae seen after massive resuscitation. This has led to the recognition that whole blood is extremely complex and does much more than carry oxygen. Resuscitation has changed recently with the adoption of damage control resuscitation which is the practice of allowing permissive hypotension, minimizing crystalloids and early aggressive use of blood products. This has led to a decrease in multiple organ dysfunction syndrome and acute respiratory distress syndrome.
Rhee
Peter
P
University of Arizona, Tucson, Arizona 85724-5063, USA. prhee@surgery.arizona.edu
D003161:Compartment Syndromes / Q000517:prevention & control; D015941:Complement Hemolytic Activity Assay; D000077324:Crystalloid Solutions; D005164:Factor IX / Q000627:therapeutic use; D015942:Factor VIIa / Q000627:therapeutic use; D006801:Humans; D006982:Hypertonic Solutions / Q000008:administration & dosage / Q000627:therapeutic use; D007262:Infusions, Intravenous / Q000009:adverse effects / Q000379:methods*; D007552:Isotonic Solutions / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D012128:Respiratory Distress Syndrome / Q000517:prevention & control* / Q000628:therapy; D012151:Resuscitation / Q000379:methods; D012771:Shock, Hemorrhagic / Q000628:therapy*
D000077324:Crystalloid Solutions; D006982:Hypertonic Solutions; D007552:Isotonic Solutions; D005164:Factor IX; D015942:Factor VIIa